Last reviewed · How we verify

NCT07381192

An Artificial Intelligence System for Multimodal, Multi-class Diagnosing Solid Pancreatic Lesions Based on Endoscopic Ultrasound

Recruiting now Last updated 2 February 2026
What this trial tests

trial testing iEUS-SPL(intelligent endoscopic ultrasound system-pancreatic solid lesion) in Endoscopic Ultrasound (EUS) in 383 participants. Currently enrolling.

Timeline
1 September 2025
Primary endpoint
30 June 2028
30 June 2028

Quick facts

Lead sponsorQilu Hospital of Shandong University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment383
Start date1 September 2025
Primary completion30 June 2028
Estimated completion30 June 2028
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Qilu Hospital of Shandong University

Who can join

18 and older, any sex, with Endoscopic Ultrasound (EUS) or Solid Pancreatic Lesion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to validate an artificial intelligence system named iEUS-SPL(intelligent endoscopic ultrasound system-solid pancreatic lesion) for detecting and multimodal, multi-class diagnosing solid pancreatic lesions during endoscopic ultrasound(EUS) examination.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Endoscopic Ultrasound (EUS)

Currently open trials in the same condition.

Other Qilu Hospital of Shandong University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07381192.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing